

Joseph I Clark

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2612452/publications.pdf>

Version: 2024-02-01

45
papers

15,634
citations

471061

17
h-index

395343

33
g-index

47
all docs

47
docs citations

47
times ranked

19742
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective. Radiographics, 2021, 41, 1387-1407.	1.4	30
2	Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. , 2019, 7, 49.		102
3	Combined radio-immunotherapy leads to complete clinical regression of stage IV Merkel cell carcinoma. BMJ Case Reports, 2019, 12, e230518.	0.2	4
4	High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. Frontiers in Oncology, 2019, 9, 1483.	1.3	10
5	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
6	Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report. , 2018, 6, 53.		2
7	A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma. , 2018, 6, 76.		14
8	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM. Clinical Genitourinary Cancer, 2017, 15, 31-41.e4.	0.9	31
9	Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. , 2017, 5, 102.		31
10	Long-term (LT) disease-free survival (DFS) of melanoma (MM) and renal cell cancer (RCC) patients following high-dose interleukin-2 (HD IL2).. Journal of Clinical Oncology, 2017, 35, e21005-e21005.	0.8	5
11	Association of improved survival (OS) and tumor control (TC) with interleukin-2 (IL2) with development of immune-related events (IREs): Data from the PROCLAIMSM registry.. Journal of Clinical Oncology, 2017, 35, 9528-9528.	0.8	0
12	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2016, 65, 1533-1544.	2.0	89
13	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncology, 2016, 2, 234.	3.4	534
14	A Prospective Analysis of High-Dose Interleukin-2 (HD IL-2) following PD-1 inhibitor therapy in patients with metastatic melanoma and renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, e21006-e21006.	0.8	2
15	Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).. Journal of Clinical Oncology, 2016, 34, 511-511.	0.8	1
16	Experience with IL-2 in metastatic renal cell carcinoma after treatment with one or more targeted therapies.. Journal of Clinical Oncology, 2016, 34, 622-622.	0.8	0
17	Update on the overall survival of patients with metastatic melanoma treated with immune checkpoint blockade following initial treatment with HD IL-2.. Journal of Clinical Oncology, 2016, 34, e21039-e21039.	0.8	0
18	Extension of overall survival in patients with metastatic renal cell carcinoma who received HD IL-2 followed by targeted therapy and/or immune checkpoint blockade from the PROCLAIM registry.. Journal of Clinical Oncology, 2016, 34, 4548-4548.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Efficacy and tolerability of high dose interleukin-2 (HD IL-2) after disease progression on targeted therapy (TT) for metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2016, 34, e16064-e16064.	0.8	0
20	Ipilimumab for the treatment of melanoma. Melanoma Management, 2015, 2, 33-39.	0.1	2
21	Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face. Case Reports in Oncological Medicine, 2015, 2015, 1-6.	0.2	8
22	The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 561-568.	3.2	133
23	Robust Differences in p16-Dependent Oropharyngeal Squamous Cell Carcinoma Distant Metastasis. Otolaryngology - Head and Neck Surgery, 2015, 153, 209-217.	1.1	15
24	Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer. Medical Oncology, 2013, 30, 358.	1.2	8
25	Pd1-1/pd1-3 (programmed death ligand-1/3) tissue expression and response to treatment with IL2 and antiangiogenic therapies.. Journal of Clinical Oncology, 2013, 31, 4521-4521.	0.8	4
26	Safety and efficacy of ipilimumab in melanoma patients who received prior immunotherapy on phase III study MDX010-020.. Journal of Clinical Oncology, 2013, 31, 9050-9050.	0.8	3
27	The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC).. Journal of Clinical Oncology, 2012, 30, 5501-5501.	0.8	30
28	Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy.. Journal of Clinical Oncology, 2012, 30, 354-354.	0.8	12
29	Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer.. Journal of Clinical Oncology, 2012, 30, e16027-e16027.	0.8	0
30	Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer, 2010, 116, 424-431.	2.0	20
31	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 2010, 363, 711-723.	13.9	13,065
32	Phase I Adjuvant Radiation With Docetaxel in High-Risk Head and Neck Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 396-400.	0.6	4
33	Phase I/II Trial of Outpatient PEG-interferon With Interleukin-2 in Advanced Renal Cell Carcinoma: A Cytokine Working Group Study. Journal of Immunotherapy, 2007, 30, 839-846.	1.2	6
34	Interleukin-2 and Cancer Therapy. , 2007, , 307-316.		1
35	Vaccine therapy of malignant melanoma. Clinical and Applied Immunology Reviews, 2006, 6, 217-230.	0.4	2
36	Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2005, 23, 133-141.	0.8	746

#	ARTICLE	IF	CITATIONS
37	Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG) Tj ETQq1 1 0.784314 rgBT / Ov 3.2 49	3.2	49
38	Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 3133-3140.	0.8	307
39	Response to paclitaxel and carboplatin in metastatic salivary gland cancer: A case report. <i>Head and Neck</i> , 2002, 24, 406-410.	0.9	28
40	Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer. <i>Lung Cancer</i> , 2001, 34, 271-277.	0.9	24
41	Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. <i>Cancer</i> , 2001, 92, 2334-2340.	2.0	51
42	Kidney Cancer: The Cytokine Working Group Experience (1986 -2001): Part I. IL-2-Based Clinical Trials. <i>Medical Oncology</i> , 2001, 18, 197-208.	1.2	27
43	Kidney Cancer: The Cytokine Working Group Experience (1986 -2001): Part II: Management of IL-2 Toxicity and Studies with Other Cytokines. <i>Medical Oncology</i> , 2001, 18, 209-220.	1.2	40
44	New therapeutic strategies for the treatment and prevention of head and neck cancer. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 2855-2872.	1.9	9
45	Multi-Institutional Study of the Angiogenesis Inhibitor TNP-470 in Metastatic Renal Carcinoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 2541-2541.	0.8	124